A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)

NCT06905197 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

140

Enrollment

INDUSTRY

Sponsor class

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG: DZD6008
DRUG: Sunvozertinib

Sponsor

Dizal Pharmaceuticals